• CD44-Mediated Metabolic Rewiring in IDH-Mutant Leukemia

  2026-07-02

  This study uncovers how CD44-driven metabolic changes underpin 2-hydroxyglutarate production and therapeutic resistance in IDH-mutant leukemia. The work identifies CD44 as a key dependency, suggesting that dual targeting of CD44 and mutant IDH1 may improve outcomes in AML.

• Species-Specific Metabolism of Ester Prodrugs: HD56 and Huma

  2026-07-02

  This study systematically dissects the pharmacokinetics and species-specific metabolism of the carboxylate ester prodrug HD56, highlighting the value of humanized mice for accurate in vivo-in vitro correlation. Findings inform the design and preclinical evaluation of ester-based therapeutics facing metabolic diversity across species.

• Zosuquidar (LY335979) 3HCl: Overcoming PROTAC Resistance in

  2026-07-01

  Explore how Zosuquidar (LY335979) 3HCl, a potent P-glycoprotein inhibitor, enables breakthrough solutions for multidrug and PROTAC resistance in cancer research. This in-depth analysis uncovers unique mechanistic insights and actionable strategies not found in standard MDR workflows.

• AR Heterogeneity Drives Therapy Responses in Prostate Cancer

  2026-07-01

  This study uncovers how distinct androgen receptor (AR) expression patterns in prostate cancer underlie divergent responses to castration and enzalutamide, highlighting BCL-2 as a key therapeutic target for resistant tumor subtypes. The findings inform precision strategies for managing castration-resistant prostate cancer and suggest combinatorial targeting as a way to overcome cellular heterogeneity.

• Nystatin (Fungicidin): Advanced Antifungal Workflows & Optim

  2026-06-30

  Nystatin (Fungicidin) from APExBIO stands out for robust inhibition of Candida and mycoplasma in both classic and next-generation antifungal workflows. This article breaks down practical protocol enhancements, troubleshooting strategies, and the latest synergy insights, including how moxidectin dramatically potentiates polyene efficacy against oral candidiasis.

• Machine Learning-Guided Prediction of LNPs for mRNA Vaccines

  2026-06-30

  This study introduces a machine learning framework to predict lipid nanoparticle (LNP) formulations for mRNA vaccine delivery, identifying key ionizable lipid substructures that drive efficacy. Experimental validation highlights Dlin-MC3-DMA as a superior ionizable cationic liposome, setting new standards for rational LNP design and accelerating translational research.

• Protease Inhibitor Cocktail: Enhancing Protein Stability in

  2026-06-29

  Unlock reproducible, high-sensitivity lipid droplet metabolism workflows with the Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) from APExBIO. This advanced protease inhibitor mixture secures protein integrity during extraction, enabling robust analysis of labile complexes such as DFCP1-ATGL in metabolic stress models.

• Tetrahydromagnolol: Precision Workflows for Peripheral CB2 A

  2026-06-29

  Tetrahydromagnolol offers researchers a powerful, CB2-selective tool for dissecting cannabinoid signaling and anti-inflammatory mechanisms, with proven superiority over magnolol. Explore robust workflow guidance, advanced experimental strategies, and troubleshooting insights that unlock its full potential in both classic and cutting-edge GPCR research.

• Perphenazine in Neuroimmunology: Beyond Dopamine Antagonism

  2026-06-28

  Explore the multifaceted role of Perphenazine as a dopamine D2 receptor antagonist in neuroimmunology and schizophrenia research. This article uniquely bridges receptor pharmacology, immune modulation, and advanced host-pathogen assay design for scientific investigators.

• BAY-826: Potent Small Molecule Inhibitor for Retinal Researc

  2026-06-27

  BAY-826 empowers researchers to dissect angiopoietin and pigment epithelium-derived factor (PEDF) signaling for retinal neuron survival with unmatched specificity. This article delivers actionable workflows, optimization tactics, and evidence-backed troubleshooting for advanced neurovascular studies.

• Deferoxamine Mesylate: Iron-Chelating Agent in Cancer & Hypo

  2026-06-26

  Deferoxamine mesylate stands apart as a versatile iron-chelating agent, enabling precise modeling of iron-dependent cell death, hypoxia signaling, and oxidative stress in advanced translational research. Its robust application—from tumor growth inhibition in breast cancer to HIF-1α-driven wound healing—makes it essential for next-generation oncology and regenerative workflows.

• Indole Analogue Tc3: A Novel Pyroptosis Inducer in Hepatic C

  2026-06-26

  The reference study introduces Tc3, a thiazolidinedione-substituted indole, as a potent inducer of gasdermin E-mediated pyroptosis in hepatic carcinoma. Through mechanistic, in vitro, and in vivo analysis, the authors demonstrate Tc3’s efficacy alone and in combination therapies, highlighting its translational potential for overcoming current therapeutic resistance.

• Nystatin (Fungicidin): Applied Workflows & Advanced Assay Ti

  2026-06-25

  Nystatin (Fungicidin) stands out for its robust, reproducible antifungal action against diverse Candida species and Aspergillus models. Explore optimized experimental setups, advanced use-cases, and troubleshooting insights to harness its full research potential with APExBIO’s trusted formulation.

• Nystatin (Fungicidin): Optimizing Antifungal Assays & Advanc

  2026-06-25

  Nystatin (Fungicidin) from APExBIO delivers reproducible antifungal activity across Candida and Aspergillus models, with robust inhibition benchmarks and effective stock handling protocols. This guide translates advanced research and troubleshooting insights into actionable workflows for high-clarity experimental outcomes.

• CD44-Driven Metabolic Rewiring in IDH1-Mutant AML: Mechanist

  2026-06-24

  This study elucidates a critical dependency in IDH-mutant acute myeloid leukemia (AML), where CD44-mediated metabolic rewiring is required to sustain the production of the oncometabolite 2-hydroxyglutarate (2-HG). By identifying CD44 as a metabolic regulator that facilitates NADPH generation for mutant IDH1 activity, the findings highlight new therapeutic vulnerabilities and inform combinatorial treatment strategies for overcoming resistance in AML.

15858 records 1/1058 page Next 12345 下5页 Last page